AAAAAA

   
Results: 1-25 | 26-35
Results: 1-25/35
Current status of thalidomide in the treatment of cancer
Authors: Rajkumar, SV
Citation: Sv. Rajkumar, Current status of thalidomide in the treatment of cancer, ONCOLOGY-NY, 15(7), 2001, pp. 867-874
Thalidomide for previously untreated indolent or smoldering multiple myeloma
Authors: Rajkumar, SV Dispenzieri, A Fonseca, R Lacy, MQ Geyer, S Lust, JA Kyle, RA Greipp, PR Gertz, MA Witzig, TE
Citation: Sv. Rajkumar et al., Thalidomide for previously untreated indolent or smoldering multiple myeloma, LEUKEMIA, 15(8), 2001, pp. 1274-1276
Thalidomide in the treatment of plasma cell malignancies
Authors: Rajkumar, SV Kyle, RA
Citation: Sv. Rajkumar et Ra. Kyle, Thalidomide in the treatment of plasma cell malignancies, J CL ONCOL, 19(16), 2001, pp. 3593-3595
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
Authors: Dispenzieri, A Lacy, MQ Kyle, RA Therneau, TM Larson, DR Rajkumar, SV Fonseca, R Greipp, PR Witzig, TE Lust, JA Gertz, MA
Citation: A. Dispenzieri et al., Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival, J CL ONCOL, 19(14), 2001, pp. 3350-3356
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
Authors: Rajkumar, SV Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Therneau, TM Kyle, RA Greipp, PR Gertz, MA
Citation: Sv. Rajkumar et al., Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation, AM J HEMAT, 68(4), 2001, pp. 269-275
Angiogenesis in multiple myeloma
Authors: Rajkumar, SV Kyle, RA
Citation: Sv. Rajkumar et Ra. Kyle, Angiogenesis in multiple myeloma, SEMIN ONCOL, 28(6), 2001, pp. 560-564
Therapeutic application of thalidomide in multiple myeloma
Authors: Kyle, RA Rajkumar, SV
Citation: Ra. Kyle et Sv. Rajkumar, Therapeutic application of thalidomide in multiple myeloma, SEMIN ONCOL, 28(6), 2001, pp. 583-587
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
Authors: Osman, K Comenzo, R Rajkumar, SV
Citation: K. Osman et al., Deep venous thrombosis and thalidomide therapy for multiple myeloma., N ENG J MED, 344(25), 2001, pp. 1951-1952
Angiogenesis in multiple myeloma
Authors: Rajkumar, SV Greipp, PR
Citation: Sv. Rajkumar et Pr. Greipp, Angiogenesis in multiple myeloma, BR J HAEM, 113(3), 2001, pp. 565-565
Translocations involving the immunoglobulin heavy-chain locus are possibleearly genetic events in patients with primary systemic amyloidosis
Authors: Hayman, SR Bailey, RJ Jalal, SM Ahmann, GJ Dispenzieri, A Gertz, MA Greipp, PR Kyle, RA Lacy, MQ Rajkumar, SV Witzig, TE Lust, JA Fonseca, R
Citation: Sr. Hayman et al., Translocations involving the immunoglobulin heavy-chain locus are possibleearly genetic events in patients with primary systemic amyloidosis, BLOOD, 98(7), 2001, pp. 2266-2268
Complete resolution of reflex sympathetic dystrophy with thalidomide treatment
Authors: Rajkumar, SV Fonseca, R Witzig, TE
Citation: Sv. Rajkumar et al., Complete resolution of reflex sympathetic dystrophy with thalidomide treatment, ARCH IN MED, 161(20), 2001, pp. 2502-2503
Prognostic value of bone marrow angiogenesis in multiple myeloma
Authors: Rajkumar, SV Leong, T Roche, PC Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Kyle, RA Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Prognostic value of bone marrow angiogenesis in multiple myeloma, CLIN CANC R, 6(8), 2000, pp. 3111-3116
FISH demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis
Authors: Fonseca, R Rajkumar, SV Ahmann, GJ Jalal, SM Hoyer, JD Gertz, MA Kyle, RA Greipp, PR Dewald, GW
Citation: R. Fonseca et al., FISH demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis, LEUK LYMPH, 39(3-4), 2000, pp. 391
Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction
Authors: Rajkumar, SV
Citation: Sv. Rajkumar, Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction, ONCOLOGY-NY, 14(12), 2000, pp. 9-10
Thalidomide in multiple myeloma
Authors: Rajkumar, SV
Citation: Sv. Rajkumar, Thalidomide in multiple myeloma, ONCOLOGY-NY, 14(12), 2000, pp. 11-16
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
Authors: Rajkumar, SV Witzig, TE
Citation: Sv. Rajkumar et Te. Witzig, A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma, CANC TR REV, 26(5), 2000, pp. 351-362
Effect of complete response on outcome following autologous stem cell transplantation for myeloma
Authors: Rajkumar, SV Fonseca, R Dispenzieri, A Lacy, MQ Witzig, TE Lust, JA Larson, D Therneau, TM Kyle, RA Litzow, MR Greipp, PR Gertz, MA
Citation: Sv. Rajkumar et al., Effect of complete response on outcome following autologous stem cell transplantation for myeloma, BONE MAR TR, 26(9), 2000, pp. 979-983
A randomized phase II and pharmacokinetic study of dacarbazine in patientswith recurrent glioma
Authors: Rajkumar, SV Reid, JM Novotny, PJ Safgren, SL Scheithauer, BW Johnson, PS Nair, S Morton, RF Hatfield, AK Krook, JE Ames, MM Buckner, JC
Citation: Sv. Rajkumar et al., A randomized phase II and pharmacokinetic study of dacarbazine in patientswith recurrent glioma, J NEURO-ONC, 49(3), 2000, pp. 255-261
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
Authors: Rajkumar, SV Gertz, MA Witzig, TE
Citation: Sv. Rajkumar et al., Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma., N ENG J MED, 343(13), 2000, pp. 972-973
Thalidomide in the treatment of relapsed multiple myeloma
Authors: Rajkumar, SV Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Kyle, RA Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Thalidomide in the treatment of relapsed multiple myeloma, MAYO CLIN P, 75(9), 2000, pp. 897-901
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
Authors: Mesa, RA Hanson, CA Rajkumar, SV Schroeder, G Tefferi, A
Citation: Ra. Mesa et al., Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia, BLOOD, 96(10), 2000, pp. 3374-3380
Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma
Authors: Fonseca, R Hoyer, JD Aguayo, P Jalal, SM Ahmann, GJ Rajkumar, SV Witzig, TE Lacy, MQ Dispenzieri, A Gertz, MA Kyle, RA Greipp, PR
Citation: R. Fonseca et al., Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma, LEUK LYMPH, 35(5-6), 1999, pp. 599-605
Monoclonal gammopathies of undetermined significance
Authors: Kyle, RA Rajkumar, SV
Citation: Ra. Kyle et Sv. Rajkumar, Monoclonal gammopathies of undetermined significance, HEMAT ONCOL, 13(6), 1999, pp. 1181
Prognostic factors in multiple myeloma
Authors: Rajkumar, SV Greipp, PR
Citation: Sv. Rajkumar et Pr. Greipp, Prognostic factors in multiple myeloma, HEMAT ONCOL, 13(6), 1999, pp. 1295
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
Authors: Rajkumar, SV Fonseca, R Witzig, TE Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma, LEUKEMIA, 13(3), 1999, pp. 469-472
Risultati: 1-25 | 26-35